Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Identification and Replication of Six Loci Associated With Gallstone Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Response to AASLD editorial/message from the president

    Research output: Contribution to journalLetterResearchpeer-review

  3. Reversal of Acute Liver Failure Due to Wilson Disease by a Regimen of High-Volume Plasma Exchange and Penicillamine

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Effect of Overweight and Obesity on Liver Biochemical Markers in Children and Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of LDL cholesterol on microvascular versus macrovascular disease: A Mendelian Randomization Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

A common loss-of-function variant in HSD17B13 (rs72613567:TA) was recently found to protect from chronic liver disease. Whether the variant confers protection from specific risk factors for liver disease is unclear. We tested the association of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general population, including 497 with cirrhosis and 113 with hepatocellular carcinoma. HSD17B13 rs72613567:TA was associated with stepwise lower levels of plasma ALT of up to 1.3 U/L in TA/TA homozygotes versus T/T homozygotes. For each TA-allele, the risk of cirrhosis and hepatocellular carcinoma was reduced by 15% and 28%, respectively. In prospective analyses, the TA-allele was associated with up to 33% lower rates of liver-related mortality in the general population, and with up to 49% reduced liver-related mortality in patients with cirrhosis. The ALT-lowering effect of rs72613567:TA was amplified by increasing adiposity, alcohol consumption, and genetic risk of fatty liver disease. The TA-allele was associated with only marginally lower ALT in lean nondrinkers with low genetic risk of hepatic steatosis. In contrast, compared with T/T homozygotes, TA/TA homozygotes had 12% to 18% lower plasma ALT among the most obese, in heavy drinkers, and in individuals carrying three or four steatogenic alleles in patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily 2 (TM6SF2). Conclusion: High risk of fatty liver disease amplifies the ALT-lowering effect of HSD17B13 rs72613567:TA in the Danish general population.

Original languageEnglish
JournalHepatology (Baltimore, Md.)
Volume71
Issue number1
Pages (from-to)56-66
Number of pages11
ISSN0270-9139
DOIs
Publication statusPublished - Jan 2020

ID: 59309547